Clinical Trial Update: ATA-100 (Formerly GNT0006) Gene Therapy Trial in Patients With LGMDR9 [Phase 1]

View source ↗

Summary

Update on Atamyo Therapeutics' ATA-100 gene therapy trial for limb-girdle muscular dystrophy type 9 (LGMDR9), currently in Phase 1 and listed as active but not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Limb-girdle Muscular Dystrophy Type

Drugs mentioned

• ATA-100

Snippet

Sponsor: Atamyo Therapeutics | Conditions: LGMDR9 | Phase 1 | Status: ACTIVE_NOT_RECRUITING